Pharma Integrates 2023 Track 1
Big Health Issues and Technology
How do we tackle some of the biggest health challenges, such as chronic conditions, respiratory and cancer?
How can we use technology to improve health outcomes, improve sustainability and create robust supply chains?
Welcome and Fireside Chat
Welcome & Opening Remarks
Susan Rienow | Country President UK, Pfizer | President, ABPI
Introduced by:
Trevor Jones CBE | Chairman, e-Therapeutics | Board Member, Respiratory Innovation Wales and Ascension Healthcare
Fireside Chat
Pharma CEO Plenary Discussion: View from the top – navigating the opportunities and challenges presented by a dynamic UK environment and achieving success.
Speakers include:
Susan Rienow | Country President UK, Pfizer | President, ABPI
Marie-Andrée Gamache | Country President | Novartis UK and Ireland
Dr Antonio Payano | Chief Executive Officer | Bayer UK & Ireland
Interviewed by:
Tamsin Berry | Head of Policy and Partnerships, AreteiaTx | Partner, Population Health Partners
Session 1: Panel Discussion followed by Q&A
AI – ‘intelligent’ or simply ‘artificial’?
‘AI, ‘data’, and ‘digital’ are the buzzwords of current innovation. How can we best apply advances in artificial intelligence, data science, and digital technology to bring better treatments to patients?
FACILITATED BY
Phil Carvil | Head of Clusters (NW) | UKRI Science and Technology Facilities Council
PANELLISTS
Jenny Barnett | Chief Executive Officer | Monument Therapeutics
Joshua Blight | Chief Executive Officer & Co-Founder | Baseimmune
Casper Wilstrup | Chief Executive Officer | Abzu
Jorge Costa | Life Sciences Industry Consultant | Emerson
Jonathan Smith | Co-Founder & Director | Veraxis
Session 2: Panel Discussion followed by Q&A
Can the NHS and pharma work together to solve the burden of long-term diseases?
As life expectancy increases, so does the economic burden of managing chronic diseases. How can we better diagnose, treat, and prevent long-term conditions such as diabetes, cardiovascular disease, and respiratory disease?
FACILITATED BY
Tim Ringrose | Chief Executive Officer | Cognitant
PANELLISTS
Ian Philp | Founder | Age Care Technologies
Sheuli Porkess | Chief Medical Officer and Business Unit Director | Precisia Life Sciences, a C2-Ai business
Rina Newton | Co-Founder | Code Clarity
Joep Hufman | Country Medical Director UK & Ireland | Bayer Pharma
Stephanie Campbell | Founder & Chief Executive Officer | OKKO Health
Session 3: Panel Discussion followed by Q&A
Partnering – for better or for worse?
CDMOs and CROs have long been well established players on the pharmaceutical scene. As our ways of working continue to evolve, how has partnering changed?
FACILITATED BY
Brennan Miles | Head of Drug Delivery | Team Consulting
PANELLISTS
Christian Jones | Chief Commercial Officer | Nanoform
David Harrison | Senior Director, Head of Device Manufacturing Partnerships | UCB
Chris Davison | Chief Executive Officer | Custom Pharma Services
Dave Wightman | Director, External Development and Manufacturing | AstraZeneca
James Fry | Partner and Head of Life Sciences | Mills & Reeve
Olivia Boyce | Director of Project Management | SK biotek
Session 4: Panel Discussion & Q&A
Technology – a new link in a broken supply chain?
The Covid pandemic brought a sharp focus on the fragility of supply chains. Has this driven a lasting trend for onshoring manufacturing capabilities and embracing new tech to streamline supply? How are distribution models changing and how quickly are we moving to greener supply chains?
FACILITATED BY
Stefan Kulik | Managing Director | Royal Mail Health
PANELLISTS
Richard Vellacott | Chief Executive Officer | BiologIC Technologies
Jagjit Singh Srai | Director of Research | University of Cambridge
Manjit Jhooty | Chief Executive Officer | Jhoots Group
Mark Buswell | Vice President, Quality Tech | GSK
Hui Yi Tee | Business Development Manager | Nanoform
Session 5: Panel Discussion & Q&A
Big CDMO, Small CDMO
The CDMO industry is evolving. With the model of the “mega CDMO” emerging, how will this shape the contract manufacturing landscape, and what are the implications for competition among smaller and speciality CDMOs?
FACILITATED BY
Christophe Le Ret | Global Marketing Director | Umicore
PANELLISTS
Steven Facer | Vice President of Business Development EU/ROW | Adare Pharma Solutions
Martin Doorbar | Chief Development Officer; Non Clinical | Ellipses Pharma
Claire Thompson | Chief Executive Officer | Agility Life Sciences
Giuliano Perfetti | Chief Executive Officer & Managing Director | Jubilant Biosys
Valeria Ciarnelli | Senior Director, Product Development | Quotient Sciences